↓ Skip to main content

64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients

Overview of attention for article published in EJNMMI Research, March 2015
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
81 Dimensions

Readers on

mendeley
64 Mendeley
Title
64Cu-DOTA-trastuzumab PET imaging and HER2 specificity of brain metastases in HER2-positive breast cancer patients
Published in
EJNMMI Research, March 2015
DOI 10.1186/s13550-015-0082-6
Pubmed ID
Authors

Hiroaki Kurihara, Akinobu Hamada, Masayuki Yoshida, Schuichi Shimma, Jun Hashimoto, Kan Yonemori, Hitomi Tani, Yasuji Miyakita, Yousuke Kanayama, Yasuhiro Wada, Makoto Kodaira, Mayu Yunokawa, Harukaze Yamamoto, Chikako Shimizu, Kazuhiro Takahashi, Yasuyoshi Watanabe, Yasuhiro Fujiwara, Kenji Tamura

Abstract

The purpose of this study was to determine whether brain metastases from HER2-positive breast cancer could be detected noninvasively using positron emission tomography (PET) with (64)Cu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-trastuzumab. PET was performed on five patients with brain metastases from HER2-positive breast cancer, at 24 or 48 h after the injection of approximately 130 MBq of the probe (64)Cu-DOTA-trastuzumab. Radioactivity in metastatic brain tumors was evaluated based on PET images in five patients. Autoradiography, immunohistochemistry (IHC), and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis were performed in one surgical case to confirm HER2 specificity of (64)Cu-DOTA-trastuzumab. Metastatic brain lesions could be visualized by (64)Cu-DOTA-trastuzumab PET in all of five cases, which might indicated that trastuzumab passes through the blood-brain barrier (BBB). The HER2 specificity of (64)Cu-DOTA-trastuzumab was demonstrated in one patient by autoradiography, immunohistochemistry, and LC-MS/MS. Cu-DOTA-trastuzumab PET could be a potential noninvasive procedure for serial identification of metastatic brain lesions in patients with HER2-positive breast cancer. UMIN000004170.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Indonesia 1 2%
Unknown 63 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 17%
Student > Ph. D. Student 10 16%
Student > Bachelor 7 11%
Student > Doctoral Student 6 9%
Student > Postgraduate 6 9%
Other 8 13%
Unknown 16 25%
Readers by discipline Count As %
Medicine and Dentistry 18 28%
Chemistry 6 9%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Agricultural and Biological Sciences 4 6%
Immunology and Microbiology 2 3%
Other 10 16%
Unknown 20 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 April 2015.
All research outputs
#20,273,512
of 22,805,349 outputs
Outputs from EJNMMI Research
#385
of 556 outputs
Outputs of similar age
#218,672
of 259,016 outputs
Outputs of similar age from EJNMMI Research
#14
of 16 outputs
Altmetric has tracked 22,805,349 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 556 research outputs from this source. They receive a mean Attention Score of 2.5. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 259,016 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.